GB-268

N/A

Report date: 2025/07/21 14:14:09

Base Information

Drug NameGB-268
Drug Alias NameGB268
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed cell death protein 1 blockersVascular endothelial growth factor inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Programmed cell death protein 1Vascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A